Josh Schimmer
Stock Analyst at Evercore ISI Group
(3.55)
# 974
Out of 4,873 analysts
129
Total ratings
53.7%
Success rate
4.55%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $2.53 | +137.15% | 2 | Jun 23, 2025 | |
| SEPN Septerna | Maintains: Overweight | $20 → $25 | $10.71 | +133.43% | 3 | May 16, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $20 → $30 | $2.77 | +983.03% | 5 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $179.05 | +56.38% | 3 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $25.79 | +190.81% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $15.76 | +217.26% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $1.61 | +1,142.24% | 2 | Mar 25, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $44.45 | +113.72% | 11 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $143.67 | +49.65% | 5 | Feb 20, 2025 | |
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $2.88 | +73.61% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $23.35 | +756.53% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $16.93 | +47.67% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.20 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $16.78 | +78.78% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.00 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.49 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $30.94 | +190.89% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.57 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $105.90 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.95 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.40 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.45 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $63.29 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.37 | +3,954.05% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $29.87 | +77.44% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $32.16 | +102.15% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $51.11 | +17.39% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.77 | +2,724.86% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.41 | +107.47% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.45 | +658.62% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $128.18 | +1.42% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $522.27 | +45.52% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $12.84 | +16.82% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $7.87 | +598.86% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.45 | +1,124.49% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.08 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.56 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $284.98 | -12.27% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $69.01 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $39.65 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.00 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $14.40 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $14.22 | +54.71% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.66 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.69 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $185.55 | -48.80% | 1 | Aug 17, 2017 |
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $2.53
Upside: +137.15%
Septerna
May 16, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $10.71
Upside: +133.43%
Rocket Pharmaceuticals
May 16, 2025
Maintains: Overweight
Price Target: $20 → $30
Current: $2.77
Upside: +983.03%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $179.05
Upside: +56.38%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $25.79
Upside: +190.81%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $15.76
Upside: +217.26%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $1.61
Upside: +1,142.24%
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $44.45
Upside: +113.72%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $143.67
Upside: +49.65%
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.88
Upside: +73.61%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $23.35
Upside: +756.53%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $16.93
Upside: +47.67%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.20
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $16.78
Upside: +78.78%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.00
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.49
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $30.94
Upside: +190.89%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.57
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $105.90
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.95
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.40
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.45
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $63.29
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.37
Upside: +3,954.05%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $29.87
Upside: +77.44%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $32.16
Upside: +102.15%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $51.11
Upside: +17.39%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.77
Upside: +2,724.86%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.41
Upside: +107.47%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.45
Upside: +658.62%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $128.18
Upside: +1.42%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $522.27
Upside: +45.52%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $12.84
Upside: +16.82%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $7.87
Upside: +598.86%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.45
Upside: +1,124.49%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.08
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.56
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $284.98
Upside: -12.27%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $69.01
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $39.65
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.00
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $14.40
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $14.22
Upside: +54.71%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $10.66
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $54.69
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $185.55
Upside: -48.80%